Navigation Links
Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Date:3/11/2009

CRANBURY, N.J., March 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's President and Chief Executive Officer John F. Crowley will be presenting at the upcoming Cowen and Company 29th Annual Healthcare Conference. Mr. Crowley's presentation is scheduled to begin on Tuesday, March 17 at 9:30 a.m. Eastern Time.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Change to Board of Directors
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
4. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
5. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
6. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
7. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
8. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
9. Amicus Therapeutics Opens Research Facility in San Diego
10. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
11. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):